MarketCap
Sarepta Therapeutics SRPT
$ 22.99
0.04%
Facebook
X
Telegram
Sarepta Therapeutics Retained Earnings | SRPT
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 1980 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.88 B | -4.21 B | -4.45 B | -3.91 B | -3.21 B | -2.85 B | -2.29 B | -1.58 B | -1.22 B | -1.17 B | -899 M | -679 M | -543 M | -431 M | -310 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -310 M | -4.88 B | -2.17 B |
Quarterly Retained Earnings Sarepta Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.55 B | -4.55 B | -4.64 B | -4.46 B | -4.66 B | -4.21 B | -4.37 B | -4.4 B | -4.41 B | -4.45 B | -4.49 B | -4.45 B | -4.43 B | -3.91 B | -3.8 B | - | -3.31 B | -3.21 B | -3.08 B | -3.04 B | -2.96 B | -2.85 B | -2.85 B | -2.85 B | -2.85 B | -2.29 B | -2.29 B | -2.29 B | -2.29 B | -1.58 B | -1.58 B | -1.58 B | -1.58 B | -1.22 B | -1.22 B | -1.22 B | -1.22 B | -1.17 B | -1.17 B | -1.17 B | -1.17 B | -899 M | -899 M | -899 M | -899 M | -679 M | -679 M | -679 M | -679 M | -543 M | -543 M | -543 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -543 M | -4.66 B | -2.47 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-421 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-198 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Codexis
CDXS
|
-607 M | $ 1.42 | 0.33 % | $ 124 M | USA |
 |
Synthetic Biologics
SYN
|
-359 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Corner Growth Acquisition Corp.
COOL
|
-6.06 M | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
-15.8 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
-83 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Cue Biopharma
CUE
|
-368 M | $ 27.67 | 2.63 % | $ 2.62 B | USA |
 |
CureVac N.V.
CVAC
|
-1.4 B | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-512 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-325 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
301 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
1.21 B | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
-307 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-156 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-246 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-189 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-1.01 B | - | 2.43 % | $ 254 M | Germany |
 |
Editas Medicine
EDIT
|
-1.63 B | $ 3.08 | 0.33 % | $ 273 M | USA |
 |
Ardelyx
ARDX
|
-947 M | $ 3.71 | 1.06 % | $ 894 M | USA |
 |
Affimed N.V.
AFMD
|
-536 M | - | -34.95 % | $ 21.5 M | Germany |
 |
EyePoint Pharmaceuticals
EYPT
|
-1.1 B | $ 4.57 | 0.21 % | $ 335 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 23.66 | 0.04 % | $ 3.01 B | USA |
 |
Assembly Biosciences
ASMB
|
-832 M | $ 36.13 | 4.38 % | $ 405 M | USA |
 |
Fate Therapeutics
FATE
|
-1.53 B | $ 2.42 | 0.61 % | $ 287 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-578 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-350 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-90 M | $ 6.66 | 5.38 % | $ 4.45 M | USA |
 |
Fortress Biotech
FBIO
|
-734 M | $ 2.71 | 0.04 % | $ 75.6 M | USA |
 |
Generation Bio Co.
GBIO
|
-703 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Anika Therapeutics
ANIK
|
60.8 M | $ 21.0 | 2.08 % | $ 301 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-454 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-1.63 B | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 208.35 | 0.16 % | $ 10.4 B | USA |
 |
GlycoMimetics
GLYC
|
-172 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
-773 M | $ 57.46 | 2.9 % | $ 1.65 B | USA |
 |
Aeterna Zentaris
AEZS
|
-20.5 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-223 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
154 M | $ 66.43 | 0.04 % | $ 12.7 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |